|
시장보고서
상품코드
1552489
세계의 조진균증 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 유형별, 치료별, 지역별 예측(2024-2032년)Global Onychomycosis Market Size, Share, Trends, Industry Analysis Report: By Type, By Treatment (Topical, Oral and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Market Forecast, 2024 - 2032. |
||||||
Polaris Market Research의 최신 조사에 따르면 세계의 조진균증 시장 규모는 2032년까지 56억 8,946만 달러에 이를 전망입니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
조진균증 시장은 진균증에 대한 인식이 증가하고 일반 시민의 의식이 향상됨에 따라 큰 성장을 이루고 있습니다. 이로 인해 발톱 곰팡이와 같은 곰팡이 감염의 조기 발견과 영향에 대한 이해가 깊어졌습니다.
2023년 9월, 미국 질병 예방 관리 센터(CDC)는 곰팡이증 계발 주간(FDAW)을 인증했습니다. 매년 CDC와 그 파트너는 곰팡이 감염에 대한 일반인의 의식을 높이기 위한 노력과 아웃리치 활동에 참여하고 있습니다. 2023년 FDAW를 향해 다양한 행사에서 진균증이 증가하는 과제, 복잡성, 심각한 영향을 강조하고 있습니다.
게다가 레이저는 식품의약국(FDA)으로부터 승인을 받고 있으며, 기술의 진보에 의해 조진균증의 치료에 레이저가 사용되게 되어 시장의 확대에 기여하고 있습니다.
Indian Dermatology Online Journal에 따르면 외용 요법과 분수 CO2 레이저를 결합하여 손톱 곰팡이 치료의 효과를 높일 수 있습니다. 발톱의 두께, 발톱 곰팡이의 범위와 유형, 세션 수, 동시 치료 등 여러 요인이 치료 결과에 영향을 미칩니다. 분수 CO2 레이저 치료는 손톱에 개구부를 만들어 42일 동안 외부 약물전달을 3-4배 개선합니다. 따라서, 네일 진균증에 대한 외용 요법과 병행하여, 전처리로서 분수 CO2 레이저를 사용하는 것이 유리합니다.
게다가, 조진균증에 대한 내복 치료는 외용 항진균제에 비해 성공률이 높고 치료 기간이 짧기 때문에 환자들 사이에서 인기가 높아지고 있습니다. 이 진균증에 대한 주요 치료법은 테르비나핀 하이드로 클로라이드의 내복입니다. 많은 제네릭 제조업체가 증가하는 발톱 진균증에 대응하기 때문에 경구 치료제를 출시하고 있습니다.
예를 들어, 2021년 6월, Glenmark Pharmaceuticals사는 네일 진균증 치료제로서 450mg과 300mg의 테오필린 서방정이 있고, 치료상 동등하고 생물학적으로 동등하다고 미국 FDA로부터 승인을 얻었습니다.
손톱 곰팡이증 시장 보고서 하이라이트
말초 손톱 갑옷 손톱 곰팡이 부문이 시장을 독점. 이는 네일 진균증 치료로 효과적인 약물에 대한 수요가 증가함에 따라 FDA에 의한 승인 수가 증가하고 있기 때문입니다.
국소 치료제는 부작용이 적기 때문에 예측 기간 동안 국소 치료제 부문이 시장을 독점했습니다.
예측기간 동안 북미가 시장을 독점한 이유는 대상 질환의 발생이 증가하고 정부 정책이 지지되었기 때문입니다.
아시아태평양은 의료 서비스에 대한 액세스가 제한되어 있으며 위생 습관이 나쁘고 도시화가 진행되고 있기 때문에 복합 연간 성장률(CAGR)이 가장 빠를 것으로 예상됩니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 조진균증 시장 인사이트
- 시장 현황
- 조진균증 시장 역학
- 성장 촉진요인과 기회
- 국소요법 수요 증가가 시장 성장을 견인
- 선진 기술의 대두가 시장의 성장을 견인
- 억제요인과 과제
- 대체요법의 존재
- 성장 촉진요인과 기회
- PESTEL 분석
- 조진균증 시장의 응용 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 조진균증 시장 : 유형별
- 주요 조사 결과
- 소개
- 원위 손톱 갑옷 조진균증
- 근위 손톱갑 아래 조진균증
제6장 세계의 조진균증 시장 : 치료별
- 주요 조사 결과
- 소개
- 국소
- 경구
- 기타
제7장 세계의 조진균증 시장 : 지역별
- 주요 조사 결과
- 소개
- 북미
- 미국
- 캐나다
- 유럽
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제8장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제9장 기업 프로파일
- Abbott
- Bausch Health Companies Inc.
- Cipla Inc.
- Merck & Co., Inc.
- Moberg Pharma AB
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Zydus Lifesciences
The global onychomycosis market size is expected to reach USD 5,689.46 million by 2032, according to a new study by Polaris Market Research. The report "Global Onychomycosis Market Size, Share, Trends, Industry Analysis Report: By Type, By Treatment (Topical, Oral and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Market Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The onychomycosis market is experiencing significant growth due to increased recognition of fungal diseases and improved public awareness. This has led to early detection and better understanding of the effects of fungal infections, such as onychomycosis.
In September 2023, the Centers for Disease Control and Prevention (CDC) recognized Fungal Disease Awareness Week (FDAW). Every year, the CDC and its partners participate in initiatives and outreach efforts to raise public awareness of fungal infections. Leading up to FDAW in 2023, various events emphasized the growing challenges, complexities, and significant impacts of fungal diseases.
Furthermore, lasers have received approval from the Food and Drug Administration (FDA), and technological advancements have led to the use of lasers in the treatment of onychomycosis, contributing to the expansion of the market.
As per the Indian Dermatology Online Journal, combining topical therapy with fractional CO2 laser can enhance the effectiveness of onychomycosis treatment. Several factors, such as nail plate thickness, extent and type of onychomycosis, number of sessions, and concurrent therapy, can influence treatment results. Fractional CO2 laser treatment involves creating openings in the nail, which improves the delivery of topical drugs by three to four times over 42 days. Therefore, using fractional CO2 laser as a pre-treatment alongside topical therapy for onychomycosis can be beneficial.
Furthermore, oral treatment for onychomycosis is becoming increasingly popular among patients due to its higher success rates and shorter treatment durations compared to topical antifungals. The main treatment for this fungal infection is oral terbinafine hydrochloride. Many generic manufacturers are introducing oral treatments to address the growing prevalence of onychomycosis.
For instance, in June 2021, Glenmark Pharmaceuticals was granted approval by the U.S. FDA for their therapeutically equivalent and bioequivalent theophylline extended-release tablets, available in 450 mg and 300 mg for the treatment of onychomycosis.
Onychomycosis Market Report Highlights
The distal subungual onychomycosis segment dominated the market. This is due to the rising number of approvals by the FDA in response to the increasing demand for more effective medications for onychomycosis treatment.
The topical segment dominated the market over the forecast period as topical treatments are associated with fewer side effects.
The North America region dominated the market over the forecast period owing to the increased occurrence of the target disease and supportive government policies.
The Asia-Pacific region is expected to grow at the fastest CAGR owing to the limited access to healthcare services, poor hygiene practices, and extensive urbanization.
The global key market players include Bausch Health Companies Inc., Moberg Pharma AB, Abbott, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., Novartis AG, Zydus Lifesciences and Sun Pharmaceutical Industries Ltd.
Polaris Market Research has segmented the onychomycosis market report based on type, treatment, and region:
Onychomycosis, Type Outlook (Revenue - USD Million, 2019 - 2032)
- Distal Subungual Onychomycosis
- Proximal Subungual Onychomycosis
- White Superficial Onychomycosis
- Others
Onychomycosis, Treatment Outlook (Revenue - USD Million, 2019 - 2032)
- Topical
- Oral
- Others
Onychomycosis, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Australia
- Malaysia
- Vietnam
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Onychomycosis Market Insights
- 4.1. Onychomycosis Market - Market Snapshot
- 4.2. Onychomycosis Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Demand for Topical Therapies is Driving the Market Growth
- 4.2.1.2. Rising Advanced Technologies is Driving the Market Growth
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Presence of Alternative Therapies
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Onychomycosis Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Onychomycosis Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 5.3. Distal Subungual Onychomycosis
- 5.3.1. Global Onychomycosis Market, by Distal Subungual Onychomycosis, by Region, 2019-2032 (USD Million)
- 5.4. Proximal Subungual Onychomycosis
- 5.4.1. Global Onychomycosis Market, by Proximal Subungual Onychomycosis, by Region, 2019-2032 (USD Million)
- 5.4.2. White Superficial Onychomycosis
- 5.4.2.1. Global Onychomycosis Market, by White Superficial Onychomycosis, by Region, 2019-2032 (USD Million)
- 5.4.3. Others
- 5.4.3.1. Global Onychomycosis Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Onychomycosis Market, by Treatment
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 6.3. Topical
- 6.3.1. Global Onychomycosis Market, by Topical, by Region, 2019-2032 (USD Million)
- 6.4. Oral
- 6.4.1. Global Onychomycosis Market, by Oral, by Region, 2019-2032 (USD Million)
- 6.5. Others
- 6.5.1. Global Onychomycosis Market, by Others, by Region, 2019-2032 (USD Million)
7. Global Onychomycosis Market, by Geography
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Onychomycosis Market Assessment, By Geography, 2019-2032 (USD Million)
- 7.3. Onychomycosis Market - North America
- 7.3.1. North America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.3.2. North America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.3.3. Onychomycosis Market - U.S.
- 7.3.3.1. U.S.: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.3.3.2. U.S.: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.3.4. Onychomycosis Market - Canada
- 7.3.4.1. Canada: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.3.4.2. Canada: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.4. Onychomycosis Market - Europe
- 7.4.1. Europe: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.4.2. Europe: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.4.3. Onychomycosis Market - UK
- 7.4.3.1. UK: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.4.3.2. UK: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.4.4. Onychomycosis Market - France
- 7.4.4.1. France: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.4.4.2. France: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.4.5. Onychomycosis Market - Germany
- 7.4.5.1. Germany: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.4.5.2. Germany: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.4.6. Onychomycosis Market - Italy
- 7.4.6.1. Italy: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.4.6.2. Italy: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.4.7. Onychomycosis Market - Spain
- 7.4.7.1. Spain: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.4.7.2. Spain: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.4.8. Onychomycosis Market - Netherlands
- 7.4.8.1. Netherlands: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.4.8.2. Netherlands: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.4.9. Onychomycosis Market - Russia
- 7.4.9.1. Russia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.4.9.2. Russia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.4.10. Onychomycosis Market - Rest of Europe
- 7.4.10.1. Rest of Europe: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.4.10.2. Rest of Europe: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.5. Onychomycosis Market - Asia Pacific
- 7.5.1. Asia Pacific: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.5.2. Asia Pacific: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.5.3. Onychomycosis Market - China
- 7.5.3.1. China: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.5.3.2. China: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.5.4. Onychomycosis Market - India
- 7.5.4.1. India: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.5.4.2. India: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.5.5. Onychomycosis Market - Malaysia
- 7.5.5.1. Malaysia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.5.5.2. Malaysia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.5.6. Onychomycosis Market - Japan
- 7.5.6.1. Japan: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.5.6.2. Japan: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.5.7. Onychomycosis Market - Indonesia
- 7.5.7.1. Indonesia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.5.7.2. Indonesia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.5.8. Onychomycosis Market - South Korea
- 7.5.8.1. South Korea: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.5.8.2. South Korea: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.5.9. Onychomycosis Market - Australia
- 7.5.9.1. Australia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.5.9.2. Australia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.5.10. Onychomycosis Market - Rest of Asia Pacific
- 7.5.10.1. Rest of Asia Pacific: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.5.10.2. Rest of Asia Pacific: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.6. Onychomycosis Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.6.2. Middle East & Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.6.3. Onychomycosis Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.6.3.2. Saudi Arabia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.6.4. Onychomycosis Market - UAE
- 7.6.4.1. UAE: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.6.4.2. UAE: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.6.5. Onychomycosis Market - Israel
- 7.6.5.1. Israel: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.6.5.2. Israel: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.6.6. Onychomycosis Market - South Africa
- 7.6.6.1. South Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.6.6.2. South Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.6.7. Onychomycosis Market - Rest of Middle East & Africa
- 7.6.7.1. Rest of Middle East & Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.6.7.2. Rest of Middle East & Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.7. Onychomycosis Market - Latin America
- 7.7.1. Latin America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.7.2. Latin America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.7.3. Onychomycosis Market - Mexico
- 7.7.3.1. Mexico: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.7.3.2. Mexico: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.7.4. Onychomycosis Market - Brazil
- 7.7.4.1. Brazil: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.7.4.2. Brazil: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.7.5. Onychomycosis Market - Argentina
- 7.7.5.1. Argentina: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.7.5.2. Argentina: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
- 7.7.6. Onychomycosis Market - Rest of Latin America
- 7.7.6.1. Rest of Latin America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
- 7.7.6.2. Rest of Latin America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Abbott
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Bausch Health Companies Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Cipla Inc.
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Merck & Co., Inc.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Moberg Pharma AB
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Novartis AG
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Pfizer Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Sun Pharmaceutical Industries Ltd.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Teva Pharmaceutical Industries Ltd.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Zydus Lifesciences
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
